LAMP2a‐mediated CMA‐selected degradation of specific substrate is key for tumor progression,[13, 15, 16] we therefore screened for the LAMP2a substrates that are responsible for aripiprazole‐induced mTOR and CRC inhibition. Here, MTOR is linked to colorectal carcinoma.